HASBROUCK HEIGHTS, N.J., Oct. 23, 2016 -- Patients can have a thorough evaluation that can identify signs of serious eye diseases at earlier stages than with other methods, reports Heights Eye Center. An appointment with a Hasbrouck Heights optometrist provides patients with the benefit of improved eye disease diagnosis and management for conditions including glaucoma, cataracts and macular degeneration. Optomap technology provides eye doctors and vision patients with enhanced diagnostic capabilities, and is performed without the need for pupil dilation. Heights Eye Center combines quality eye care with the latest technology for exceptional vision services and treatment.
Optomap retinal exams provide patients with enhanced accuracy in the early detection of eye diseases and health issues. An optomap image can provide data that goes beyond commonly diagnosed vision conditions, including cataracts, glaucoma and macular degeneration. An optomap retinal exam provides eye doctors with detailed imaging that can show early signs of those at risk of hypertension, heart disease, stroke and diabetes. The exam using an optomap retinal scanner is comfortable, quick and painless. A patient peers into the optomap space a single eye at a time and a flash of light indicates when the image is captured. Images are available for immediate review.
Traditional exams show very little of the actual retina, with eye doctors only seeing 15 percent of the retina in a single image. Optomap retinal scanning provides significantly more information to eye doctors and patients, capturing over 80 percent of the retina in one image. This data can detect signs of eye conditions sooner, which may prevent permanent vision impairment or blindness. Both children and adults can benefit from an optomap retinal exam.
“Optomap technology is a safe and effective tool to evaluate patient eye health and give important information on serious eye and health conditions,” said Dr. James Aversa. “As an experienced optometrist, I can share that optomap technology has allowed us improved capabilities of eye disease detection and eye health maintenance. This advanced scanning laser technology allows optometrists to examine the retina and capture a wide field digital image of eye structures and conditions. Optomap can be used safely and without discomfort on children and adults providing more information about a patient’s eye health. Early diagnosis helps patients and doctors work towards improved outcomes.”
Dr. James Aversa, optometrist in Hasbrouck Heights at Heights Eye Center, serves eye care needs of residents of Hasbrouck Heights and the surrounding area. Patients can expect comprehensive vision and eye care combined with the latest optical technology for the entire family. Services include non-surgical vision correction, dry eye treatment, Miboflo lid treatment, digital retinal photography, BlephEx, computerized visual field testing, LASIK evaluations and Gems genetic testing.
Call (201) 288-1109 to learn about optomap technology or visit http://www.heightseyecenter.net/ for more details on their eye care services.
Heights Eye Center, (201) 288-1109


BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 



